New hope for hepatitis b patients: switching to TAF after relapse
NCT ID NCT04496882
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 260 chronic hepatitis B patients who stopped their antiviral medication and then had a flare-up. They are switched to a drug called tenofovir alafenamide (TAF) to see if it can control the virus and improve liver health. The goal is to measure how many patients achieve undetectable virus levels and normal liver enzyme tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir alafenamide (TAF), a drug to control hepatitis B virus
What this could lead to
If successful, this could show that switching to TAF is an effective way to manage hepatitis B flare-ups after stopping other antivirals, helping patients achieve viral suppression and liver health.
What could go wrong
This is a phase 4 trial, so the drug is already approved, but it may not work for everyone. The study is open-label and lacks a placebo group, which could bias results. Some patients may still experience side effects or incomplete viral control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Buddhist Tzu Chi General Hospital, Da-Lin Branch
Chiayi City, Taiwan
-
Buddhist Tzu-Chi General Hospital Taipei Branch
Taipei, Taiwan
-
Chia-Yi Christian Hospital
Chiayi City, Taiwan
-
E-da hospital
Kaohsiung City, Taiwan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
National Taiwan University Hospital ,Hsin-Chu Branch
Hsinchu, Taiwan
-
National Taiwan University Hospital, Yun-Lin branch
Douliu, Taiwan
-
Taipei City Hospital, Renai Branch
Taipei, Taiwan